Progress in research of P2Y12 receptor antagonists antiplatelet drugs
DONG Hui-yu
CHENG Xian-hua
ZHONG Wen-ying
WU Yan-zhuo
XU Ming-bo
Abstract：Thrombotic diseases have threaten people's health seriously and the research of antithrombotic drugs has drawn wide attention.Inhibiting the P2Y~ receptor on platelet surface can prevent the happening of thrombus through inhibiting the aggregation of platelets.Therefore,studying P2Y12 receptor antagonists is an important direction towards antithrombosis therapy.Currently,clopidogrel,prasugrel,ticagrelor and cangrelor are the main P2Y12 receptor antagonists in clinical practice,which have achieved great therapeutic effect.However,they have their own disadvantages respectively.For example,clopidogrel resistance,increasing bleeding risk and limited application.Under this condition,the development of novel antiplatelet drugs is particularly important.ClopNPT as a novel P2Y12 receptor antagonist is in the research stage,which has shown desirable pharmacokinetic results and sufficient antiplatelet advantages.This article reviewed all the aspects above in research for P2Y12 receptor antagonists antiplatelet drugs.
Keywords：P2Y12 receptor antagonistsantiplatelet drugsclopidogrelCYP2C19 gene polymorphisms
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 1406-1411 )